| Added by | llasorsa |
|---|---|
| Group name | EquipeMY |
| Item Type | Journal Article |
| Title | Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma |
| Creator | Quesada et al. |
| Author | Stanislas Quesada |
| Author | Emmanuelle Samalin |
| Author | Simon Thezenas |
| Author | Lakhdar Khellaf |
| Author | Anne Mourregot |
| Author | Fabienne Portales |
| Author | Thibault Mazard |
| Author | Marc Ychou |
| Author | Antoine Adenis |
| Abstract | BACKGROUND: We hypothesized that perioperative FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) might be used as an alternative to standard FLOT (docetaxel, 5-fluorouracil, leucovorin, and oxaliplatin) in patients with locally advanced oesogastric adenocarcinomas (OGA), particularly those with frailties. PATIENTS AND METHODS: We reviewed the charts of 61 consecutives patients treated with FOLFOX for resectable OGA to estimate overall survival, recurrence-free survival, and safety. RESULTS: The median follow-up was 69.7 (range=3.6-97.9) months. Few patients experienced grade 3 adverse events during the preoperative (n=6; 10%) and postoperative (n=6; 16%) phases. One patient experienced a fatal grade 5 adverse events (cardiogenic shock). Median overall survival was 51.7 months [95% confidence interval (CI)=31.6-93.2 months] and the 5-year survival rate was 44.4% (95% CI=30.3%-57.5%). CONCLUSION: Regarding its comparable efficacy and its favourable toxicity profile, perioperative FOLFOX is a reasonable alternative to FLOT for frail patients with resectable OGA. |
| Publication | Anticancer Research |
| Volume | 42 |
| Issue | 1 |
| Pages | 185-193 |
| Date | 2022-01 |
| Journal Abbr | Anticancer Res |
| Language | eng |
| DOI | 10.21873/anticanres.15472 |
| ISSN | 1791-7530 |
| Library Catalog | PubMed |
| Extra | PMID: 34969724 |
| Tags | Adenocarcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, CA-19-9 Antigen, Carcinoembryonic Antigen, Disease-Free Survival, Docetaxel, Esophagogastric Junction, Female, Fluorouracil, Humans, Leucovorin, Male, Middle Aged, Neoadjuvant Therapy, Oesogastric adenocarcinoma, Organoplatinum Compounds, oxaliplatin, Perioperative Period, Proportional Hazards Models, Stomach Neoplasms |
| Date Added | 2022/08/30 - 16:11:03 |
| Date Modified | 2024/10/10 - 16:31:43 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
